Stocklytics Platform
Asset logo for symbol QGEN
QIAGEN NV
QGEN61
$41.55arrow_drop_down0.55%-$0.23
Asset logo for symbol QGEN
QGEN61

$41.55

arrow_drop_down0.55%

Performance History

Chart placeholder
Key Stats
Open$41.45
Prev. Close$41.78
EPS1.52
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range40.91
41.72
52 Week Range34.74
47.70
Ratios
EPS1.52

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$857.46
Perf. (24h)
arrow_drop_up1.00%$8.56
Market Cap$764.35B
Price$565.33
Perf. (24h)
arrow_drop_up0.17%$0.98
Market Cap$519.41B
Price$154.69
Perf. (24h)
arrow_drop_down0.46%-$0.73
Market Cap$374.04B
Price$125.77
Perf. (24h)
arrow_drop_up1.22%$1.52
Market Cap$314.70B

About QIAGEN NV (QGEN)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Thierry Bernard
Headquarters
Venlo
Employees
6200
Exchange
NYSE
add QIAGEN NV to watchlist

Keep an eye on QIAGEN NV

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is QIAGEN NV's (QGEN) price per share?

The current price per share for QIAGEN NV (QGEN) is $41.55. The stock has seen a price change of -$0.23 recently, indicating a -0.55% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for QIAGEN NV (QGEN)?

For QIAGEN NV (QGEN), the 52-week high is $47.7, which is 14.8% from the current price. The 52-week low is $34.74, the current price is 19.6% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is QIAGEN NV (QGEN) a growth stock?

QIAGEN NV (QGEN) has shown an average price growth of 0.41% over the past three years. It has received a score of 43 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying QIAGEN NV as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is QIAGEN NV (QGEN) stock price performance year to date (YTD)?

As of the latest data, QIAGEN NV (QGEN) has a year-to-date price change of -7.67%. Over the past month, the stock has experienced a price change of -0.81%. Over the last three months, the change has been 3.88%. Over the past six months, the figure is -10.69%. Looking at a longer horizon, the five-year price change stands at 1.93%.

help
Is QIAGEN NV (QGEN) a profitable company?

QIAGEN NV (QGEN) has a net income of $341.3M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 62.23% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 21.41% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.97B, although specific revenue growth data is currently not available. The gross profit is $1.22B. Operating income is noted at $445.25M. Furthermore, the EBITDA is $712.96M.

help
What is the market capitalization of QIAGEN NV (QGEN)?

QIAGEN NV (QGEN) has a market capitalization of $9.27B. The average daily trading volume is 1.11M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level